Get the Latest Sangamo Stock Quote and Company News

To get the latest Sangamo stock quote, you can check the NASDAQ website or use a reliable financial news platform.

Sangamo's stock symbol is SGMO, so be sure to use that when searching for the latest quote.

You can also find up-to-date company news and announcements on the Sangamo website under the Investor Relations section.

Sangamo is a biotechnology company that focuses on gene editing and gene therapy, so you may want to keep an eye on news related to these areas.

Sangamo Therapeutics stock took a significant hit after Pfizer terminated their pact for a gene therapy product.

Sangamo Therapeutics regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe hemophilia.

This move is a major shift in the company's plans for the product, which was previously being co-developed with Pfizer.

The Sangamo stock quote provides a clear picture of the company's performance. Its market capitalization is a significant $563,237,000.

The stock's performance is also reflected in its day-to-day fluctuations. On any given day, the stock can range from $1.08 to $1.15.

Here are some key statistics that summarize the stock's performance:

Sangamo Therapeutics Inc has seen a significant increase in revenue, with $176.23 million in 2023, a 58.34% jump from the previous year's $111.30 million.

The company's market value is substantial, with a market capitalization of $563,237,000. It's listed on the NASDAQ exchange.

Sangamo Therapeutics Inc is a clinical-stage genomic medicine company, focusing on translating science into medicines for serious diseases.

The company's stock performance has been volatile, with a previous close of $1.13 and a day range of $1.08 to $1.15. The year range is even more dramatic, from $0 to $3.

Here's a summary of the company's stock performance:

The company's losses have also increased, with -$257.83 million in 2023, a 34.1% rise from the previous year's -$192.49 million.

Sangamo Therapeutics Inc's diluted EPS (TTM) is -$1.24, and revenue growth YOY is -94.8%.

Stock crashes can be a scary thing, but it's essential to understand what's happening. Sangamo Therapeutics shares plummeted more than 50% after Pfizer pulled out of their deal to co-develop a hemophilia drug.

This kind of market volatility can be unsettling, especially for investors who have their money tied up in the stock. The biopharma firm's announcement sent shockwaves through the market.

It's worth noting that the stock crash was a direct result of the deal falling through. This highlights the importance of staying informed about company partnerships and developments.

The sudden drop in stock value can be a significant financial hit for investors. It's a reminder to always do your research and stay up-to-date on market news.